By Julian Pecquet - 01/17/12 08:01 PM EST
A spokeswoman for the FDA said in an e-mail that the agency "did not believe that a recall was warranted because of the following reasons:
• Given the very low risk of a medication mix-up, and that these are medically necessary products, this approach should also help to mitigate to some degree the likely shortage of these products given the manufacturing issues at the Lincoln, Nebraska facility.
• For prescription opioids the pharmacist serves as a second level of protection against such mix-ups. In many, if not most, cases the dispensing pharmacist would have counted the tablets and would likely have identified any stray tablets prior to dispensing to a patient; and
• FDA and Endo Pharmaceuticals are recommending additional steps to further reduce the already low risk of a medication mix-up by having patients and pharmacists check tablets.
"It is also important to note that for Novartis OTC products, FDA has concluded that we have no reports of adverse events related to product mix-ups stemming from errant product."
Bono Mack, a high-ranking member of the Energy and Commerce Committee, is a leader of congressional efforts to limit painkiller overdoses, which now surpass the numbers of deaths from cocaine and heroin combined.
Update: This post was updated at 5 p.m. with comment from the FDA